Stimulants: Therapeutic Actions in ADHD
The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Abstract
Stimulants such as methylphenidate and amphetamine are currently the most common treatment for attention deficit hyperactivity disorder (ADHD). For years, it was assumed that stimulants had paradoxical calming effects in ADHD patients, whereas stimulating 'normal' individuals and producing locomotor activation in rats. It is now known that low doses of stimulants focus attention and improve executive function in both normal and ADHD subjects. Furthermore, the seminal work of Kuczenski and Segal showed that low, oral doses of methylphenidate reduce locomotor activity in rats as well. Berridge et al have now shown that these low doses produce marked increases in norepinephrine and dopamine release in the prefrontal cortex, whereas having only subtle effects on subcortical catecholamine release. ihe prefrontal cortex regulates behavior and attention using representational knowledge, and imaging and neuropsychological studies have shown that the prefrontal cortex is weaker in subjects with ADHD. This cortical area is very sensitive to levels of catecholamines: moderate levels engage postsynaptic alpha2A-adrenoceptors and D1 receptors and improve prefrontal regulation of behavior and attention, while high levels impair prefrontal function via alpha1-adrenoceptors and excessive D1 receptor stimulation. Administering low doses of methylphenidate to rats improves the working memory and attentional functions of the prefrontal cortex, while high doses impair working memory and produce…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Stimulants, such as those used to treat attention-deficit/hyperactivity disorder (ADHD), preferentially modulate central DA and, to a lesser extent, NE systems (Arnsten, 2006).”
From Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder (2014) · cites this paper as Arnsten, 2006
In the citing paper
“For college students with ADHD who have difficulties with attention and neuropsychological deficits (NPDs; e.g., difficulties with EFs) due to dopamine deficits, stimulant medication helps these students by increasing dopamine to typical levels (Arnsten, 2006; Dela Peña et al., 2015; Willcutt, 2015).”
From Effects of stimulant medication on neuropsychological functioning in college students without ADHD. (2026) · cites this paper as Arnsten, 2006
In the citing paper
“stimulants like methylphenidate and amphetamine, which increase prefrontal catecholamines, have commonly been used to treat cognitive dysfunction such as working memory impairments in patients with ADHD (Arnsten 2006, Pietrzak et al 2006).”
From Prefrontal cortex executive processes affected by stress in health and disease (2018) · cites this paper as Arnsten 2006, Pietrzak et al 2006
Citations
Cites
Inhibition and the right inferior frontal cortex
Aron, A. R., Robbins, T. W., & Poldrack, R. A. (2004) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2004.02.010 · Cited by 3,197 · cited 2×
“The right inferior prefrontal cortex is particularly important for behavioral inhibition (reviewed in Aron et al, 2004).”
BackgroundCellular basis of working memory
Goldman-Rakic, P. S. (1995) · Neuron · doi:10.1016/0896-6273(95)90304-6 · Cited by 2,663 · cited 2×
“Moderate levels of D1/D5 receptor stimulation suppress delay-related firing for nonpreferred spatial directions (ie ‘noise’), and thus enhance spatial tuning (Williams and Goldman-Rakic, 1995; Vijayraghavan et al, 2006).”
BackgroundMolecular genetics of attention-deficit/hyperactivity disorder
Faraone, S. V., Perlis, R. H., Doyle, A. E., Smoller, J. W., Goralnick, J. J., Holmgren, M. A., & Sklar, P. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.024 · Cited by 2,357 · cited 2×
“ADHD is often an inherited disorder, and many of the genes associated with ADHD code for molecules involved with catecholamine transmission (reviewed in Faraone et al, 2005).”
BackgroundVan Tol, H. H. M., Bunzow, J. R., Guan, H.-C., Sunahara, R. K., Seeman, P., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,014 · cited 1×
“It should be noted that the D4 receptor has very high affinity for norepinephrine (Van Tol et al, 1991) and should really be considered a catecholamine receptor.”
BackgroundPrinciples of Frontal Lobe Function
(2002) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195134971.001.0001 · Cited by 1,665
Castellanos, F. X. (2002) · JAMA · doi:10.1001/jama.288.14.1740 · Cited by 1,646 · cited 2×
“Many of these studies have also found reduced volume of cerebellum, caudate, and corpus callosum (Seidman et al, 2005; Castellanos et al, 2002).”
BackgroundModulation of memory fields by dopamine Dl receptors in prefrontal cortex
Williams, G. V., & Goldman-Rakic, P. S. (1995) · Nature · doi:10.1038/376572a0 · Cited by 1,593 · cited 1×
“Moderate levels of D1/D5 receptor stimulation suppress delay-related firing for nonpreferred spatial directions (ie ‘noise’), and thus enhance spatial tuning (Williams and Goldman-Rakic, 1995; Vijayraghavan et al, 2006).”
BackgroundImpairment of social and moral behavior related to early damage in human prefrontal cortex
Anderson, S. W., Bechara, A., Damasio, H., Tranel, D., & Damasio, A. R. (1999) · Nature Neuroscience · doi:10.1038/14833 · Cited by 1,539 · cited 1×
“Lesions in the ventromedial prefrontal cortex can impair regulation of emotion, and result in inappropriate social behaviors such as aggression (Anderson et al, 1999).”
BackgroundDissociation in prefrontal cortex of affective and attentional shifts
Dias, R., Robbins, T. W., & Roberts, A. C. (1996) · Nature · doi:10.1038/380069a0 · Cited by 1,527 · cited 1×
“Similar results have been seen in animals, where prefrontal cortex lesions impair attentional regulation in monkeys (Malmo, 1942; Bartus and Levere, 1977; Dias et al, 1996), and rats (Muir et al, 1996).”
ResultADHD and The Nature of Self-Control
Barkley, R. A., & Wasserstein, J. (2000) · Journal of Cognitive Psychotherapy · doi:10.1891/0889-8391.14.1.111 · Cited by 1,513
Cited by
Items 101–200 of 538
Distinct Age-Dependent Effects of Methylphenidate on Developing and Adult Prefrontal Neurons
Urban, K. R., Waterhouse, B. D., & Gao, W.-J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.018 · Cited by 57
The Neurobiology of Attention-Deficit/Hyperactivity Disorder
Chamberlain, S. R., Robbins, T. W., & Sahakian, B. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.009 · Cited by 63
Inhibition of GSK3 attenuates amphetamine-induced hyperactivity and sensitization in the mouse
Enman, N. M., & Unterwald, E. M. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.03.027 · Cited by 51
Does dopaminergic reward system contribute to explaining comorbidity obesity and ADHD?
Liu, L., Li, B., Yang, J., & Wang, Y. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2007.10.012 · Cited by 62
Collicular dysfunction in attention deficit hyperactivity disorder
Overton, P. G. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2007.11.016 · Cited by 61
“At present, the most common treatment for ADHD is pharmacotherapy with psychostimulants – either methylphenidate (Ritalin) or amphetamines [3].”
BackgroundHand, D. J., Fox, A. T., & Reilly, M. P. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283305ee1 · Cited by 59
“Unauthorized reproduction of this article is prohibited. doses used for ADHD in humans (Kuczenski and Segal, 2002; Arnsten, 2006).”
BackgroundPerformance monitoring and behavioral adaptation during task switching: An fMRI study
von der Gablentz, J., Tempelmann, C., Münte, T. F., & Heldmann, M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.11.024 · Cited by 53
Methylphenidate Effects on Prefrontal Functioning During Attentional-Capture and Response Inhibition
Pauls, A. M., O'Daly, O. G., Rubia, K., Riedel, W. J., Williams, S. C. R., & Mehta, M. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.028 · Cited by 57
Aripiprazole in Children with Attention-Deficit/Hyperactivity Disorder
Findling, R. L., Short, E. J., Leskovec, T. J., Townsend, L. D., Demeter, C., McNamara, N., & Stansbrey, R. J. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0124 · Cited by 56
“Although the precise etiology of ADHD has not been elucidated, dopaminergic neural transmission, particularly in the prefrontal cortex, has been implicated in the pathophysiology of this condition (see reviews by Arnsten 2006; Biederman and Faraone 2005; Pliszka 2005).”
Wiley, M. D., Poveromo, L. B., Antapasis, J., Herrera, C. M., & Bolaños Guzmán, C. A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.188 · Cited by 48
“Psychostimulant medications are effective for the treatment of ADHD, and methylphenidate (MPH; Ritalin) is one of the most prescribed therapeutic agents (Arnsten, 2006; Zito et al, 2000).”
Punja, S., Xu, D., Schmid, C. H., Hartling, L., Urichuk, L., Nikles, J., & Vohra, S. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.03.026 · Cited by 56
Atomoxetine facilitates attentional set shifting in adolescent rats
Cain, R. E., Wasserman, M. C., Waterhouse, B. D., & McGaughy, J. A. (2011) · Developmental Cognitive Neuroscience · doi:10.1016/j.dcn.2011.04.003 · Cited by 55
A pilot open label prospective study of memantine monotherapy in adults with ADHD
Surman, C. B. H., Hammerness, P. G., Petty, C. R., Spencer, T. J., Doyle, R., Napolean, S., Chu, N., Yorks, D. M., & Biederman, J. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.623716 · Cited by 53
“Although conventional therapies for ADHD are thought to work in part through regulation of catecholamine activity (Biederman and Spencer 1999; Arnsten 2006), the glutamate system may be an alternative target for ADHD intervention, given its participation in a range of brain functions, including…”
BackgroundAnimal model of methylphenidate's long-term memory-enhancing effects
Carmack, S., Howell, K. K., Rasaei, K., Reas, E. T., & Anagnostaras, S. (2014) · Learning & Memory · doi:10.1101/lm.033613.113 · Cited by 53
Becker, M., Repantis, D., Dresler, M., & Kühn, S. (2022) · Human Brain Mapping · doi:10.1002/hbm.25949 · Cited by 53
“ADHD has been associated with weakened prefrontal cortex function (Arnsten, 2006), altered DMN–FPN interactions (Sripada”
BackgroundBurke, A. R., Forster, G. L., Novick, A. M., Roberts, C. L., & Watt, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.013 · Cited by 49
“Performance in mPFC DA-dependent cognitive tasks is also improved by low dose methylphenidate (Arnsten, 2006), via preferentially increasing extracellular DA levels in the mPFC (Berridge et al., 2006).”
BackgroundDimensions of Impulsivity Are Associated with Poor Spatial Working Memory Performance in Monkeys
James, A. S., Groman, S. M., Seu, E., Jorgensen, M., Fairbanks, L. A., & Jentsch, J. D. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4508-07.2007 · Cited by 48
“Attention deficit/hyperactivity disorder (ADHD) is a multidimensional disorder that involves alterations in temperament (impulsivity), behavior (hyperactivity), and cognition (inattention, poor working memory) (Solanto, 2001; Castellanos and Tannock, 2002; Aron and Poldrack, 2005; Arnsten, 2006).”
BackgroundPharmacotherapy in autism spectrum disorders, including promising older drugs warranting trials
Hellings, J. A. (2023) · World Journal of Psychiatry · doi:10.5498/wjp.v13.i6.262 · Cited by 52
Animal models to guide clinical drug development in ADHD: lost in translation?
Wickens, J. R., Hyland, B. I., & Tripp, G. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01412.x · Cited by 52
“An alternative theory is that the therapeutic effects of psychostimulants are mediated by norepinephrine (Pliszka et al., 1996; Arnsten, 2006).”
BackgroundNeuropharmacology in Pediatric Brain Injury: A Review
Pangilinan, P. H., Argento, A. G., Shellhaas, R. A., Hurvitz, E. A., & Hornyak, J. E. (2010) · PM&R · doi:10.1016/j.pmrj.2010.07.007 · Cited by 51
“Their echanism of action is through the upregulation of both opamine and norepinephrine, primarily within the prefronal cortex [96].”
BackgroundHnrnph1 Is A Quantitative Trait Gene for Methamphetamine Sensitivity
Yazdani, N., Parker, C. C., Shen, Y., Reed, E. R., Guido, M. A., Kole, L. A., Kirkpatrick, S. L., Lim, J. E., Sokoloff, G., Cheng, R., et al. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005713 · Cited by 49
“103 Sensitivity to the locomotor stimulant response to MA is heritable and may share a genetic basis 104 with the addictive, neurotoxic, and therapeutic properties of amphetamines [8, 12-15].”
BackgroundThe neurobiology of executive functions
Hunter, S. J., Hinkle, C. D., & Edidin, J. P. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511977954.005 · Cited by 49
ADHD 24/7: Circadian clock genes, chronotherapy and sleep/wake cycle insufficiencies in ADHD
Korman, M., Palm, D., Uzoni, A., Faltraco, F., Tucha, O. M., Thome, J., & Coogan, A. N. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2018.1523565 · Cited by 50
Bush, G. (2008) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2007.11.002 · Cited by 49
“Convergent data from neuroimaging, neuropsychologic, genetics, and neurochemical studies have implicated frontostriatal network abnormalities as the likely cause of ADHD [1–11,17,18], (see articles by Castellanos and Tannock, elsewhere in this issue).”
BackgroundCortes, D. S., Skragge, M., Döllinger, L., Laukka, P., Fischer, H., Nilsson, M. E., Hovey, D., Westberg, L., Larsson, M., & Granqvist, P. (2018) · Social Cognitive and Affective Neuroscience · doi:10.1093/scan/nsy068 · Cited by 48
“…effect on the minds of nloaded from https://academ ic.oup.com /scan/article-abstract/13/9/921/5077396 by guest on 03 M ay 2019 high-absorption scorers, akin to the calming effects of low doses of the central stimulant medication observed especially on hyperactive individuals (Arnsten, 2006).”
BackgroundReed, D. D., Naudé, G. P., Gelino, B. W., & Amlung, M. T. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.011 · Cited by 48
Dopamine/serotonin releasers as medications for stimulant addictions
Rothman, R. B., Blough, B. E., & Baumann, M. H. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00919-9 · Cited by 47
RibaséS, M., Ramos-Quiroga, J. A., HerváS, A., Sánchez-Mora, C., Bosch, R., Bielsa, A., Gastaminza, X., Lesch, K.-P., Reif, A., Renner, T. J., et al. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.584905 · Cited by 36
The Prevention and Treatment of Gambling Disorders: Some Art, Some Science
Derevensky, J. L. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.024 · Cited by 47
Sensitization of Incentive Salience and the Transition to Addiction
Warlow, S. M., Baumgartner, H. M., Freeland, C. M., Naffziger, E. E., Olney, J. J., Berridge, K. C., & Robinson, M. J. F. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.006 · Cited by 47
Zhu, J., Spencer, T. J., Liu‐Chen, L., Biederman, J., & Bhide, P. G. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.015 · Cited by 48
Park, S., Kim, B.-N., Cho, S.-C., Kim, Y., Kim, J.-W., Lee, J. Y., Hong, S.-B., Shin, M., Yoo, H. J., Im, H., et al. (2014) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph110706743 · Cited by 47
“The response time variability we found to be correlated with the urine phthalate metabolite concentrations is an indicator of inconsistency of attentional performance, which has been proposed as a leading endophenotype for ADHD [34].”
BackgroundPunja, S., Zorzela, L., Hartling, L., Urichuk, L., & Vohra, S. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002312 · Cited by 40
A new mouse model of ADHD for medication development
Majdak, P., Ossyra, J. R., Ossyra, J. M., Cobert, A. J., Hofmann, G. C., Tse, S., Panozzo, B., Grogan, E. L., Sorokina, A., & Rhodes, J. S. (2016) · Scientific Reports · doi:10.1038/srep39472 · Cited by 39
The impact of perinatal stress on the functional maturation of prefronto-cortical synaptic circuits
Bock, J., & Braun, K. (2011) · Progress in brain research · doi:10.1016/b978-0-444-53884-0.00023-3 · Cited by 47
Wooters, T. E., Neugebauer, N. M., Rush, C. R., & Bardo, M. T. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301477 · Cited by 47
“From a clinical perspective, it is interesting to note that methylphenidate (Ritalin) is the most commonly prescribed pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD), a behavioral disorder characterized by excessive levels of activity, impulsivity, and inattention (Arnsten, 2006; Solanto et al, 200…”
BackgroundPurkinje Cell-Specific Knockout of Tyrosine Hydroxylase Impairs Cognitive Behaviors
Locke, T. M., Fujita, H., Hunker, A. C., Johanson, S., Darvas, M., du Lac, S., Zweifel, L. S., & Carlson, E. S. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00228 · Cited by 46
“Delayed alternation, a term for several similar tasks requiring working memory which can be evaluated in humans and animals, is deficient in neuropsychiatric disorders associated with prefrontal cortical catecholaminergic dysfunction including autism, Alzheimer’s disease, attention deficit disorder, schizophrenia, and…”
BackgroundStructural brain network topology underpinning ADHD and response to methylphenidate treatment
Griffiths, K. R., Braund, T. A., Kohn, M. R., Clarke, S. D., Williams, L. M., & Korgaonkar, M. S. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01278-x · Cited by 46
Neurobiological Foundations of Behavioral Addictions
Vaccaro, A. G., & Potenza, M. N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.016 · Cited by 45
Bush, G., Holmes, J., Shin, L. M., Surman, C., Makris, N., Mick, E., Seidman, L. J., & Biederman, J. (2013) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2012.09.004 · Cited by 41
“While a few studies have provided insights (Arnsten, 2006; Seneca et al., 2006; Logan et al., 2007; Pliszka, 2007; Chamberlain et al., 2009; Takano et al., 2009), the neural mechanisms by which ATMX exerts therapeutic effects remain unresolved.”
Improved prefrontal activity in AD/HD children treated with atomoxetine: A NIRS study
Araki, A., Ikegami, M., Okayama, A., Matsumoto, N., Takahashi, S., Azuma, H., & Takahashi, M. (2014) · Brain and Development · doi:10.1016/j.braindev.2014.03.011 · Cited by 45
Training sensory signal-to-noise resolution in children with ADHD in a global mental health setting
Mishra, J., Sagar, R., Joseph, A. A., Gazzaley, A. H., & Merzenich, M. M. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.45 · Cited by 45
Faraone, S. V., McBurnett, K., Sallee, F. R., Steeber, J., & López, F. A. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.09.005 · Cited by 44
Targeting the dopamine system in the treatment of attention-deficit/hyperactivity disorder
Staller, J. A., & Faraone, S. V. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.4.351 · Cited by 44
Gronier, B. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.11.002 · Cited by 44
“While low doses of MPH improve attention and cognition in adult and ADHD patients, higher doses tend to have the opposite effect impairing cognitive function in human and potently increasing locomotion activity in animals (Arnsten, 2006).”
BackgroundMindfulness-Based Interventions Applied to Addiction Treatments
Kechter, A., & Black, D. S. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.040 · Cited by 44
Considering the Overlap and Nonoverlap of Compulsivity, Impulsivity, and Addiction
Blum, A. W., & Grant, J. E. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.038 · Cited by 44
Neurobiology of Substance Addictions
Christie, N. C., & Bechara, A. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.015 · Cited by 44
Increased microsaccade rate in individuals with ADHD traits
Panagiotidi, M., Overton, P., & Stafford, T. (2017) · Journal of Eye Movement Research · doi:10.16910/10.1.6 · Cited by 42
Multiple Memory Systems, Addiction, and Health Habits: New Routes for Translational Science
Stacy, A. W., Pike, J. R., & Lee, A. Y. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.017 · Cited by 43
Tanning as an Addiction: The State of the Research and Implications for Intervention
Miller, K. A., & Mays, D. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.037 · Cited by 43
Schulte, E. M., Schiestl, E. T., & Gearhardt, A. N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.035 · Cited by 43
Umemoto, A., Lukie, C. N., Kerns, K. A., Müller, U., & Holroyd, C. B. (2014) · Cognitive Affective & Behavioral Neuroscience · doi:10.3758/s13415-014-0298-3 · Cited by 43
“, Ritalin, Concerta), which increases extrasynaptic DA levels by blocking DA reuptake in the striatum (see Cragg & Rice, 2004, for a review; Kuczenski & Segal, 1975; Wilens, 2008), normalizes ACC hypoactivity (Bush, 2009), and improves the behavioral and cognitive symptoms of ADHD (Arnsten, 2006; Rubia et al., 2009; W…”
BackgroundGeracioti, T. D., Jefferson-Wilson, L., Strawn, J. R., Baker, D. G., Dashevsky, B. A., Horn, P. S., & Ekhator, N. N. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.01.023 · Cited by 44
“However, it should be noted that diethylpropion, methylphenidate, and amphetamine all increase noradrenergic as well as dopaminergic signaling (Raiteri et al., 1975; Geranton et al., 2003; Kuczenski and Segal, 2005; Arnsten, 2006; Han and Gu, 2006; Santamaria and Arias, 2010).”
BackgroundSchmitz, F., Pierozan, P., Rodrigues, A. F., Biasibetti, H., Grunevald, M., Pettenuzzo, L. F., Scaini, G., STRECK, E. L., Netto, C. A., & Wyse, Â. T. D. S. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9987-y · Cited by 43
Nagashima, M., Monden, Y., Dan, I., Dan, H., Tsuzuki, D., Mizutani, T., Kyutoku, Y., Gunji, Y., Momoi, M. Y., Watanabe, E., et al. (2014) · Neurophotonics · doi:10.1117/1.nph.1.1.015001 · Cited by 43
Jafarinia, M., Mohammadi, M., Modabbernia, A., Ashrafi, M., Khajavi, D., Tabrizi, M., Yadegari, N., & Akhondzadeh, S. (2012) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2242 · Cited by 42
“Stimulants (including methylphenidate) are commonly used for treatment of ADHD and are thought to exert their therapeutic effect through inhibition of reuptake of dopamine and norepinephrine (Arnsten, 2006; Mohammadi and Akhondzadeh, 2011).”
BackgroundBehavioral Economics and Addictive Disorders
Jarmolowicz, D. P., & Schneider, T. D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.005 · Cited by 42
Prevention and Treatment of Compulsive Buying Disorder
Galimov, A., & Black, D. W. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.027 · Cited by 42
Blum, K., Roy, A. K., Podesta, A., Modestino, E. J., Steinberg, B., Gondré-Lewis, M. C., Baron, D. A., Thanos, P. K., Lott, L., Badgaiyan, S., et al. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.031 · Cited by 42
Prevention and Treatment of “Food Addiction”
Davis, C., & Mason, A. E. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.023 · Cited by 42
Human Neurobiological Approaches to Hedonically Motivated Behaviors
Burger, K. S., Shearrer, G. E., & Sadler, J. R. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.009 · Cited by 42
Feedback Models for Gambling Control: The Use and Efficacy of Online Responsible Gambling Tools
Griffiths, M. D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108632591.034 · Cited by 42
Atomoxetine Attenuates Dextroamphetamine Effects in Humans
Sofuoglu, M., Poling, J., Hill, K., & Kosten, T. (2009) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990903383961 · Cited by 35
“These findings further support the contribution of the noradrenergic system activation in mediating the acute effects of amphetamines (6).”
ResultDelay aversion: Effects of 7-OH-DPAT, 5-HT1A/1B-receptor stimulation and d-cycloserine
van den Bergh, F. S., Bloemarts, E., Groenink, L., Olivier, B., & Oosting, R. S. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.11.007 · Cited by 43
Zhang, C.-L., Feng, Z.-J., Liu, Y., Ji, X.-H., Peng, J.-Y., Zhang, X.-H., Zhen, X.-C., & Li, B.-M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051910 · Cited by 41
“Interestingly in a recent report, mice mutant with one subtype of the DGK, DGKb, have been shown to express various dysfunctions similar with ADHD symptoms.”
BackgroundInfluentialCatecholaminergic Innervation of the Lateral Nucleus of the Cerebellum Modulates Cognitive Behaviors
Carlson, E. S., Hunker, A. C., Sandberg, S. G., Locke, T. M., Geller, J. M., Schindler, A. G., THOMAS, S. A., Darvas, M., Phillips, P. E. M., & Zweifel, L. S. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.2406-20.2021 · Cited by 41
COMT Val108/158Met Polymorphism and the Modulation of Task-Oriented Behavior in Children with ADHD
Sengupta, S. M., Grizenko, N., Schmitz, N., Schwartz, G. J., Bellingham, J., Polotskaia, A., Ter-Stepanian, M., Goto, Y., Grace, A. A., & Joober, R. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.85 · Cited by 42
Reinforcement, Dopamine and Rodent Models in Drug Development for ADHD
Tripp, G., & Wickens, J. R. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0132-y · Cited by 42
“We have not undertaken a comprehensive review because a number of thorough reviews have recently appeared in the literature dealing separately with animal models [1–8], reinforcement theories [9–12], and psychopharmacology of ADHD [13–15].”
BackgroundLi, J., Li, Z., Wang, S., Qi, F., Zhao, L., Lv, H., & Li, A. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2238-z · Cited by 41
“…presynaptic neuron and increasing the release of these monoamines into the extraneuronal space (Handen et al. 1992; Farias et al. 2010; Pliszka et al. 1996; Puumala and Sirvio 1998; Arnsten 2006; Salehi et al. 2010; So et al. 2008; Ruocco et al. 2009; Bloch et al. 2009; Rowles and Findling 2010).”
BackgroundEarly pathogenic care and the development of ADHD-like symptoms
Dahmen, B., Puetz, V. B., Herpertz‐Dahlmann, B., & Konrad, K. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0809-8 · Cited by 40
Yang, Z., Kelly, C. A. M., Castellanos, F. X., Leon, T. L., Milham, M. P., & Adler, L. A. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0243 · Cited by 40
Obermeit, L. C., Cattie, J. E., Bolden, K. A., Marquine, M. J., Morgan, E. E., Franklin, D. R., Atkinson, J. H., Grant, I., & Woods, S. P. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2013.08.010 · Cited by 39
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript symptomatology may be a form of self-medication, especially considering the benefits associated with stimulants in controlling ADHD symptomatology (Arnsten, 2006).”
BackgroundRuocco, L. A., Silva, M. A. D. S., Topic, B., Mattern, C., Huston, J. P., & Sadile, A. G. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.02.005 · Cited by 39
“Psychostimulant drugs, such as methylphenidate (Ritalin) or D-amphetamine, are effective in improving the main symptoms of ADHD (Arnsten, 2006), and are considered the first-line therapy for patients with ADHD (Horst and Hendren, 2005; Madaan et al.”
BackgroundNagashima, M., Monden, Y., Dan, I., Dan, H., Mizutani, T., Tsuzuki, D., Kyutoku, Y., Gunji, Y., Hirano, D., Taniguchi, T., et al. (2014) · Neurophotonics · doi:10.1117/1.nph.1.2.025007 · Cited by 39
Sable, H. J. K., Eubig, P. A., Powers, B. E., Wang, V. C., & Schantz, S. L. (2009) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2008.12.006 · Cited by 39
“A reduction in PFC DA activity is believed to underlie the deficits in inhibitory control in ADHD children (Sullivan and Brake 2003) and pharmacotherapies that increase DA release are commonly used for treatment (Arnsten 2006).”
BackgroundGarner, A. A., Hansen, A. A., Baxley, C., & Ross, M. J. (2017) · Sports Medicine · doi:10.1007/s40279-017-0829-5 · Cited by 38
Rodriguez, J. S., Morris, S. M., Hotchkiss, C. E., Doerge, D. R., Allen, R. R., Mattison, D. R., & Paule, M. G. (2009) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2009.08.011 · Cited by 38
“[4] have shown that high doses of MPH produce stereotypic behaviors in monkeys, such as increased vocalization and self-grooming and intense idiosyncratic behavior, while others have reported adverse side effects in children [3,12] but positive behavioral and cognitive effects at lower doses (for review see [1,39]).”
BackgroundRugino, T. A. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a913 · Cited by 38
Shim, S.-H., Hwangbo, Y., Yoon, H.-J., Kwon, Y., Lee, H.-Y., Hwang, J.-A., & Kim, Y. (2015) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2015.1014834 · Cited by 38
Orinstein, A. J., & Stevens, M. C. G. (2014) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2014.05.012 · Cited by 38
“The results also support proposed frontoparietal deficits in ADHD-I (Diamond, 2005), a finding that is consistent with targets of norepinephrine pathways implicated in ADHD (Arnsten, 2006) and oddball-elicited ERPs (Nieuwenhuis et al.”
ResultPrescription Stimulant Use and Hospitalization for Psychosis or Mania: A Population-Based Study
Cressman, A. M., Macdonald, E. M., Huang, A., Gomes, T., Paterson, M. J., Kurdyak, P. A., Mamdani, M. M., & Juurlink, D. N. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000406 · Cited by 37
Hernaus, D., & Mehta, M. A. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.06.057 · Cited by 37
Rubinsten, O., Bedard, A., & Tannock, R. (2008) · The Open Psychology Journal · doi:10.2174/1874350100801010011 · Cited by 37
Peña, I. D., & Cheong, J. H. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0037-2 · Cited by 36
“…of this confound, however, is not established given the controversial findings in preclinical and clinical studies regarding the cognitive effects of long-term methylphenidate use (Arnsten and Dudley 2005; Arnsten 2006; LeBlanc-Duchin and Taukulis 2007; Dommet et al. 2008; Scherer et al. 2010).”
BackgroundSeu, E., & David Jentsch, J. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.08.007 · Cited by 31
“This paradoxical slowing effect induced by MPH is reportedly associated with the acute administration of low doses of stimulants and may contribute to their efficacy in treating behavioral and cognitive symptoms of ADHD (Arnsten, 2006).”
BackgroundSalatino‐Oliveira, A., Genro, J. P., Zeni, C., Polanczyk, G. V., Chazan, R., Guimarães, A. P., Callegari-Jacques, S. M., Rohde, L. A., & Hutz, M. H. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.03.025 · Cited by 36
Birn, R. M., Converse, A. K., Rajala, A. Z., Alexander, A. L., Block, W. F., McMillan, A. B., Christian, B. T., Filla, C., Murali, D., Hurley, S. A., et al. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.2513-18.2018 · Cited by 36
“Methylphenidate (MPH; e.g., Ritalin) is one of the most common psychostimulants prescribed to treat children with attention deficit hyperactivity disorder (ADHD) (Arnsten, 2006).”
BackgroundOral methylphenidate improves spatial learning and memory in pre- and periadolescent rats.
Zhu, N. W., Weedon, J., & Dow-Edwards, D. L. (2007) · Behavioral Neuroscience · doi:10.1037/0735-7044.121.6.1272 · Cited by 36
Schmitz, F., Pierozan, P., Rodrigues, A. F., Biasibetti, H., Grings, M., Zanotto, B., Coelho, D. M., Vargas, C. R., Leipnitz, G., & Wyse, A. T. S. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0289-1 · Cited by 35
Robinson, A. M., Eggleston, R. L., & Bucci, D. J. (2012) · Behavioral Neuroscience · doi:10.1037/a0030488 · Cited by 29
“…Hopkins, & Bucci, 2011; Russell, 2007; Sagvolden et al., 2005) as well as dysregulated dopaminergic and noradrenergic neurotransmission (Heal, Smith, Kulkarni, & Rowley, 2008; Russell, 2000; 2002; Solanto & Conners, 1982) that may underlie ADHD in some individuals (Arnsten, 2006; Biederman, 2005).”
Ramon‐Duaso, C., Gener, T., Consegal, M., Fernández-Avilés, C., Gallego, J., Castarlenas, L., Swanson, M. S., de la Torre, R., Maldonado, R. J., Puig, M. V., et al. (2018) · Cerebral Cortex · doi:10.1093/cercor/bhy164 · Cited by 35
Xu, T., Ma, Q., Spealman, R. D., & Yao, W. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07073.x · Cited by 35
Dopamine-Dependent Periadolescent Maturation of Corticostriatal Functional Connectivity in Mouse
Galiñanes, G. L., Taravini, I. R. E., & Murer, M. G. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4421-08.2009 · Cited by 34
“Our findings in mice with neonatal dopamine-depleting lesions parallel remarkably well some observations in ADHD, such as the delayed maturation of caudate volume (Castellanos et al., 2002), the striatal hypoactivity revealed in brain imaging studies (Rubia et al., 1999; Teicher et al., 2000; Durston, 2003), and the r…”
BackgroundInfluentialTenenbaum, Y. S., Weizman, A., & Rehavi, M. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.04.007 · Cited by 38
“Methylphenidate treatment was associated with improved spatial working memory and response inhibition in the prefrontal cortex in ADHD children and adults (Arnsten, 2006).”
BackgroundWagner, A. K., Sokoloski, J. E., Chen, X., Harun, R., Clossin, D. P., Khan, A. S., Andes-Koback, M., Michael, A. C., & Dixon, C. E. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06155.x · Cited by 34
Kim, B., Kim, J.-W., Kang, H., Cho, S.-C., Shin, M., Yoo, H., Hong, S.-B., & Lee, D. S. (2010) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.090168 · Cited by 35
Effects of methylphenidate treatment in children with ADHD: a multimodal EEG/fNIRS approach
Dolu, N., Altınkaynak, M., Güven, A., Özmen, S., Demirci, E., İzzetoğlu, M., & Pektaş, F. (2018) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2018.1542779 · Cited by 33
“The psychostimulant methylphenidate (MPH) which enhances the activation of the striatum and prefrontal cortex, is one of the widely used psychostimulant to treat ADHD [3].”
BackgroundJang, S., Choi, J., Oh, J., Yeom, J., Hong, N., Lee, N., Kwon, J. H., Hong, J., Kim, J., & Kim, E. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.564618 · Cited by 33
Novick, A. M., Forster, G. L., Hassell, J. E., Davies, D. R., Scholl, J. L., Renner, K. J., & Watt, M. J. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.05.032 · Cited by 33
“Psychostimulants primarily exert their pharmacological effect by blocking catecholamine transporters (NETand DAT; Arnsten, 2006; Fleckenstein et al., 2007).”
BackgroundInfluential
Metadata
- Authors
- Arnsten, A. F. T.
- Affiliations
- Yale University (US)
- Corresponding author
- Arnsten, Amy F T
- ORCID
- Arnsten, Amy F T
- Venue
- Neuropsychopharmacology
- Published
- 2006-07-19
- Volume
- 31
- Issue
- 11
- Pages
- 2376-2383
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1989057449
- Cited by
- 473
- References
- 110
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 18 · 2023: 14 · 2022: 19 · 2021: 20 · 2020: 59 · 2019: 11 · 2018: 20 · 2017: 13 · 2016: 30 · 2015: 16 · 2014: 23 · 2013: 27 · 2012: 36
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Yale University
- Shire
- National Institutes of Health (5r21mh066393-03)
- National Institute on Aging (R37AG006036, R37 AG06036)
- National Institute of Mental Health (R21-MH066393)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
- Keywords
- attention deficit hyperactivity disorder, stimulant medication, methylphenidate, amphetamine, prefrontal cortex, norepinephrine, dopamine, catecholamines, alpha2-adrenoceptors, dopamine D1 receptor, alpha1-adrenoceptors, working memory, executive function, attention, locomotor activity
- MeSH terms
- Central Nervous System Stimulants, Animals, Attention Deficit Disorder with Hyperactivity, Catecholamines, Dose-Response Relationship, Drug, Humans, Methylphenidate, Prefrontal Cortex
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.